GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immunome Inc.
Immunome, a biotech focused on oncology, shares reflect the progress of its immunology research. Its price trajectory is highly volatile and depends on the results of its preclinical and clinical programs and the potential of its scientific platform.
Share prices of companies in the market segment - Pharma immune
Immunome (IMNM) is a biopharmaceutical company using its proprietary platform to discover antibodies derived from the human immune system's memory to develop new treatments for cancer and infections. We classify it in the Pharmaceuticals/Immunology sector. The chart below illustrates the dynamics of this innovative biotech sector.
Broad Market Index - GURU.Markets
Immunome is a biopharmaceutical company that uses its platform for analyzing human immune system memory to discover new antibodies against cancer and infections. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
IMNM - Daily change in the company's share price Immunome Inc.
Shares of Immunome, a biotech company, are highly volatile. Change_co measures market reaction to clinical trial data in the fields of immunology and oncology. This metric is an important component of formulas on System.GURU.Markets that evaluate innovative early-stage companies.
Daily change in the price of a set of shares in a market segment - Pharma immune
Immunome, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IMNM's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Immunome is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows average fluctuations in this industry, providing context for evaluating Immunome stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immunome Inc.
Immunome is a biotech company working in the field of immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Immunome, Inc. is a biotech company using a unique antibody discovery platform to develop drugs for cancer and infectious diseases. Its stock price reflects both the potential of its scientific platform and the risks associated with clinical trials, which is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunome is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immunome Inc.
The performance of Immunome, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its oncology drugs, which are based on analysis of the human immune response, and which determines its future.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immunome is a biotech company that uses a unique platform to discover antibodies derived from the human immune system's memory to combat cancer and infectious diseases. The chart below reflects the overall sentiment in the immunopharma sector, where Immunome is pursuing breakthrough solutions.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunome, Inc. is a biotech company developing antibodies for the treatment of cancer and infectious diseases. Its stock price is driven by news of clinical trials and partnerships. The company's performance is unrelated to the market and represents a risky bet on the success of its scientific platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immunome Inc.
Immunome is a biotech company specializing in immunology. Its shares exhibit high weekly volatility, responding to the release of preclinical and clinical trial data, as well as news of partnerships with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Immunome is a biotech company whose stock thrives on news about its own research. Comparing its weekly performance with the biotech sector reveals its unique trajectory. The chart clearly demonstrates how news about its antibody discovery platform drives stock movements independent of overall industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Immunome, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
IMNM - Market capitalization of the company Immunome Inc.
Immunome's market capitalization is a pure bet on innovation in immuno-oncology. This early-stage biotech's stock price reflects not revenue, but investor confidence in its antibody discovery platform. Its extreme volatility illustrates how news about preclinical and early clinical trials can create or destroy value.
IMNM - Share of the company's market capitalization Immunome Inc. within the market segment - Pharma immune
Immunome is a biopharmaceutical company using a unique approach to analyzing the human immune response to discover new antibodies for the treatment of cancer and infectious diseases. Its sector share reflects the potential of its research platform. The chart below is an indicator of the market's confidence in its ability to discover breakthrough drugs.
Market capitalization of the market segment - Pharma immune
Immunome develops antibodies for the treatment of cancer and infectious diseases, targeting new immune system targets. The chart below shows the overall market capitalization of the immunopharmaceuticals sector. Its dynamics reflect both scientific breakthroughs and investor willingness to fund risky but potentially breakthrough research.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Immunome line on the chart represents the cutting edge of immunology. The company searches for antibodies in the blood of recovered patients to create new drugs. Its market cap is a bet that the human body has already developed responses to the most complex diseases. It's a visualization of a risky but promising approach in biotech.
Book value capitalization of the company, segment and market as a whole
IMNM - Book value capitalization of the company Immunome Inc.
Immunome's book value is its scientific and financial capital. This consists of the intellectual property in its antibody discovery platform and funds for preclinical and clinical trials. The chart below shows how this biotech company manages its capital as it develops new cancer treatments.
IMNM - Share of the company's book capitalization Immunome Inc. within the market segment - Pharma immune
Immunome is a biotech company hunting for antibodies to fight diseases. Its core assets are not its manufacturing plants, but its cutting-edge laboratories and scientific platform. The chart shows a minimal share of physical assets, as the company's value is concentrated in its discoveries and intellectual property.
Market segment balance sheet capitalization - Pharma immune
Biopharmaceuticals are primarily science, making Immunome a relatively "lightweight" company. Its value lies in its antibody patents and research data. Compared to the capital-intensive pharmaceutical sector, its model appears highly capital-efficient, as it doesn't require owning large R&D plants.
Book value of all companies included in the broad market index - GURU.Markets
Immunome's assets include cutting-edge laboratories and a technology platform for rapidly discovering antibodies that could form the basis for new drugs. Its book value reflects the resources needed to conduct this complex biotech research. The chart shows the physical weight of this innovative company in the pharmaceutical sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immunome Inc.
For biotech company Immunome, book value is the cash in its bank accounts and lab. The market price is higher because investors are paying for the potential of its antibody discovery platform, which could lead to new drugs. The chart shows how the market values this scientific engine.
Market to book capitalization ratio in a market segment - Pharma immune
Immunome is a biotech company developing cancer treatments. Its market capitalization is based on expectations for the future success of its scientific platform. This chart demonstrates the vast gap between its book value (primarily cash) and the valuation of investors buying into the hope of a breakthrough.
Market to book capitalization ratio for the market as a whole
Immunome is a biotech company developing cancer treatments based on the analysis of the human immune response. Its book value is primarily cash, and its market capitalization is a bet on the success of its scientific platform. This metric illustrates how biotech valuation depends on expectations of future breakthroughs rather than current assets.
Debts of the company, segment and market as a whole
IMNM - Company debts Immunome Inc.
Immunome, a biotech company specializing in immunology, is raising capital, including debt, to fund its research and clinical programs. For an early-stage company, this is a way to accelerate the development of potential drugs. This chart shows how Immunome is investing in its scientific potential to achieve breakthroughs.
Market segment debts - Pharma immune
Immunome is a biotech company specializing in developing antibodies to treat cancer and infectious diseases. Being in the research stage, the company has no stable revenue stream. This chart shows how Immunome uses its capital, including potential debt financing, to advance its candidates through the expensive stages of clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immunome Inc.
Immunome develops antibodies to fight cancer and infectious diseases, which requires massive, long-term investments in research. This chart shows how the biotech company finances its operations with debt. High leverage may indicate investor confidence in its platform, but it also suggests high risks before drug approval.
Market segment debt to market segment book capitalization - Pharma immune
Immunome is a biotech company developing antibodies for cancer treatment. Clinical trials require massive financial investments over many years. This chart shows how the company finances its research, comparing its debt structure to the broader picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Immunome develops innovative cancer treatments based on analysis of the human immune response. Biotechnology requires massive and risky investments over many years. Does the company prefer debt financing or shareholder dilution? This chart provides a general overview of the debt burden in the economy, which can be used to evaluate Immunome's financial strategy.
P/E of the company, segment and market as a whole
P/E - Immunome Inc.
Immunome is a biotech company using a unique antibody discovery platform to develop drugs against cancer and infectious diseases. This chart reflects the high expectations and risks inherent in early-stage research. The valuation may fluctuate dramatically depending on news about the progress of clinical trials.
P/E of the market segment - Pharma immune
Immunome is a biotech company that uses a unique platform to discover new therapeutic antibodies for cancer and infectious diseases by analyzing the human immune response. This chart shows the average rating for immunopharmaceuticals, helping to understand how the market values Immunome's innovative approach to drug discovery.
P/E of the market as a whole
Immunome is a biotech company developing antibodies for cancer treatment. Is its valuation a reflection of the general investor appetite for risky biotech assets, as measured by this chart? Or is it a unique bet on its scientific platform and the potential for clinical developments that could take off regardless of market conditions?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immunome Inc.
Immunome is a biopharmaceutical company developing antibodies to treat cancer and infectious diseases. This chart shows analysts' confidence in the commercial potential of its scientific platform. Any positive news about clinical trials could sharply increase future revenue expectations, turning scientific developments into real profits.
%20P%2FE%20Immunome%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immunome-Inc.&v=1772612428566 "Chart of the company's future (projected) P/E Immunome Inc.")
Future (projected) P/E of the market segment - Pharma immune
Immunome develops antibodies to combat cancer and infectious diseases using a unique platform for analyzing the human immune response. The company is currently in clinical trials. The chart shows expectations across the entire immunopharmaceutical industry, allowing market confidence in Immunome's technology to be compared with those of its closest competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772612428581 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Immunome, Inc. is a biotech company developing antibodies for cancer treatment. The valuation of such companies is based on the expectation of successful clinical trials. This chart of overall market sentiment is important because it shows how much investors are willing to risk and invest in innovative, but not yet profitable, medical developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612428597 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immunome Inc.
Immunome develops antibodies for the treatment of oncological and infectious diseases. The company is in clinical trials and does not yet have commercial products. The presented performance does not reflect sales revenue, but rather net losses due to high R&D costs. This is the price of creating innovative drugs of the future.
Profit of companies in the market segment - Pharma immune
Immunome develops antibodies to combat cancer and infectious diseases using a unique approach to analyzing the human immune response. This chart reflects the financial health of the biotech sector. For companies in the development stage, it illustrates the investment climate: growing profits in the industry attract the capital needed to fund their breakthrough research.
Overall market profit
Immunome, Inc. is a biotechnology company that uses the human immune system to discover and develop new antibodies to treat cancer and infectious diseases. Its valuation is based on the potential of its scientific platform. The overall economic environment, reflected in this chart, influences the investment climate, which is critical to funding its cutting-edge research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immunome Inc.
Immunome is developing a new generation of antibodies to combat cancer and infectious diseases using a unique platform for analyzing the human immune response. This chart aggregates analyst opinions on the likelihood of clinical trial success and the potential of the company's future drugs, which is key to evaluating a biotech startup.
%20profit%20of%20the%20company%20Immunome%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immunome-Inc.&v=1772612428660 "Graph of future (projected) profit of the company Immunome Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Immunome is a biotechnology company focused on developing innovative antibodies for the treatment of oncology. Like many companies in the research stage, its prospects depend on the success of its developments. The forecast presented here for the entire immunotherapy segment reflects the market's confidence in the potential of this field and the potential future value of breakthrough technologies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772612428671 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Immunome is a biotech company focused on developing innovative immune-based therapies. While its primary driver is successful clinical trials, the overall market profit forecast, shown in the chart, is important for attracting investment. Economic optimism increases investor risk appetite.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612428679 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immunome Inc.
Immunome is a biopharmaceutical company developing antibodies for the treatment of cancer and infectious diseases. Because the company is in the research stage, it may not be profitable. This chart shows how the market values the scientific potential and future sales of its platform, demonstrating the value investors place on its developments.
P/S market segment - Pharma immune
Immunome develops innovative cancer treatments based on the analysis of patients' immune responses. Like many biotech companies, its valuation is determined by the potential for future drug sales. This chart, which reflects the average industry valuation, provides insight into how investors' expectations for Immunome's breakthrough technology align with overall trends.
P/S of the market as a whole
Immunome is a biotech company that uses a unique approach to discovering antibodies to fight cancer and infectious diseases. Its current revenue is minimal, and its market cap is based on the potential of its platform. This chart shows how the market values its actual revenue, highlighting the significant premium investors are willing to pay for Immunome's future scientific breakthroughs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immunome Inc.
Immunome is a biotech company developing antibodies to fight cancer and infectious diseases. Its current valuation is largely unrelated to its current revenues, which are minimal. This chart is essentially a barometer of investor faith in the company's scientific platform and its ability to bring successful drugs to market in the coming years.
%20P%2FS%20Immunome%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immunome-Inc.&v=1772612428814 "The graph of the company's future (projected) P/S Immunome Inc.")
Future (projected) P/S of the market segment - Pharma immune
Immunome is a biotech company developing a new class of oncology drugs based on antibodies derived from the immune systems of patients who have successfully overcome cancer. The data in the chart shows average revenue expectations for the immunotherapy sector. This allows us to assess how optimistic the market is about the breakthrough potential of Immunome's platform compared to competitors.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772612428878 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Immunome develops antibody-based drugs to combat cancer and infectious diseases. Investor optimism, evident in this chart, is largely driven by breakthroughs in biotech. Immunome's success in developing new treatments directly impacts the market's belief that medical innovation will be a powerful driver of future economic growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612428908 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immunome Inc.
This chart shows the revenue of Immunome, Inc., a biopharmaceutical company focused on the discovery and development of antibodies for the treatment of cancer and infectious diseases. Revenue at this stage is primarily generated by partnerships and grants. The chart's dynamics reflect the company's success in raising funding for its cutting-edge research.
Sales of companies in the market segment - Pharma immune
Immunome, Inc. is a biopharmaceutical company using a cutting-edge platform to discover and develop antibodies for the treatment of oncology and infectious diseases. This chart reflects the dynamics of the entire segment. Immunome's success in developing new therapeutics could not only generate significant revenue but also expand the scope of the entire immunotherapy market.
Overall market sales
Immunome is a biotech company working in the field of immunology. Its growth, like many research-stage companies, depends on the availability of capital. This graph of total market revenue reflects the health of the economy, which influences investor willingness to fund cutting-edge scientific research and long-term projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immunome Inc.
Immunome develops antibodies for the treatment of cancer and infectious diseases. For a biotech company in the research stage, this chart shows forecast sales, not current sales. It reflects analysts' expectations for the success of clinical trials and future demand for its drugs.
%20sales%20of%20the%20company%20Immunome%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immunome-Inc.&v=1772612428979 "Schedule of future (projected) sales of the company Immunome Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Immunome uses a unique platform to discover new antibodies from the human immune system's memory to combat diseases such as cancer. The company is at the forefront of biotech innovation. This graph reflects projected growth rates for the entire immunotherapy segment, where Immunome strives to achieve breakthroughs with its drug candidates.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772612428996 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Immunome is developing innovative cancer treatments at the forefront of biotechnology. Funding for such companies is highly dependent on the overall risk appetite in the economy. This chart serves as an indicator of the overall business climate, which determines whether investors are willing to invest in breakthrough but long-term projects that shape the future of medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612429004 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immunome Inc.
Immunome develops antibodies for the treatment of cancer and infectious diseases. While in clinical trials, the company does not generate revenue but invests in research. This chart shows the dynamics of its net losses—the necessary costs of developing innovative drugs that could radically change therapeutic approaches in the future.
Market segment marginality - Pharma immune
Immunome is a biotech company using its proprietary platform for discovering antibodies derived from the human immune system's memory to develop new treatments for cancer and infectious diseases. Profitability is a long-term goal. This graph reflects research investment. Investors evaluate it in the context of the platform's potential for creating innovative drugs.
Market marginality as a whole
Immunome develops cancer treatments by studying how the human immune system fights disease. Their approach is based on identifying unique antibodies in patients who have successfully overcome cancer. Against this backdrop of overall profitability, Immunome's work is a bet on the future. Success in their research could create a product with enormous profitability, independent of overall cycles.
Employees in the company, segment and market as a whole
Number of employees in the company Immunome Inc.
Immunome is a biotech company focused on discovering and developing antibodies for cancer treatment. The size of its team directly reflects its research capabilities. The growth in this graph reflects the expansion of its scientific platform and the progress of new drug candidates from discovery to clinical development.
Share of the company's employees Immunome Inc. within the market segment - Pharma immune
Immunome uses a unique approach to fighting disease by studying the human immune system's response to create new antibodies. This chart shows the company's share of the overall talent pool in its biotech segment. Growing this figure signifies an expanding team of talented scientists, which directly accelerates the discovery and development of potentially breakthrough drugs.
Number of employees in the market segment - Pharma immune
Immunome, Inc. is a biopharmaceutical company that uses the human immune system to discover and develop new therapeutic antibodies. This chart reflects the talent pool in the cutting-edge field of immunology. The growing number of scientists and lab technicians in this segment indicates high investment activity and scientific breakthroughs aimed at creating a new generation of drugs against cancer and infections.
Number of employees in the market as a whole
Immunome develops innovative cancer treatments based on the analysis of the human immune response. The company is at the forefront of immuno-oncology, attracting significant investment in research. This chart demonstrates how biotech breakthroughs and the growth of companies like Immunome are creating highly skilled jobs and stimulating the scientific sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immunome Inc. (IMNM)
Immunome, Inc. is a biotech company developing innovative cancer treatments. This chart reflects the market's valuation of its intellectual capital. The company has few physical assets in the research stage; its primary asset is its scientific platform and potential drugs in development. The chart shows the high future value the market places on the work of each of the company's scientists.
%20of%20the%20company%20Immunome%20Inc.%20(IMNM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immunome-Inc.-IMNM&v=1772612429067 "Chart of market capitalization per employee (in thousands of dollars) of the company Immunome Inc. (IMNM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Immunome develops innovative cancer treatments based on the analysis of the human immune response. Like many biotech companies, its value is determined by its intellectual property and development potential. This chart shows the high market valuation of this unique scientific platform per employee, reflecting investor expectations.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772612429075 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Immunome is a biotech company using a unique approach to antibody discovery to develop cancer drugs. This chart reflects the valuation of its innovative research platform. The company's entire value is derived from its scientific potential. This indicator demonstrates the value the market places on the work of a small but highly qualified team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612429104 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immunome Inc. (IMNM)
Immunome is a biotech company focused on discovering new classes of antibodies for the treatment of cancer and infectious diseases. It's a science-intensive R&D business. At this stage, this chart shows the intensity of research expenditures, not profit. It reflects the amount of capital the company is investing in each of its scientists in the race for the next breakthrough drug.
%20Chart%20Immunome%20Inc.%20(IMNM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immunome-Inc.-IMNM&v=1772612429109 "Company Profit Per Employee (in thousands of dollars) Chart Immunome Inc. (IMNM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Immunome (IMNM) is a biotech company developing antibodies to treat cancer and infectious diseases. It is a clinical-stage R&D company. This graph shows a negative loss per employee, which is typical for this industry. The metric reflects the cost of research per scientist per year.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772612429120 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Immunome is a clinical-stage biotech company using its platform to "interrogate" human B cells to discover new antibodies against cancer and infections. The company is not profitable. This chart shows the operating loss per employee. It reflects the "cost" of their R&D platform and the rate at which they spend capital on discovering new drug candidates.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612429134 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immunome Inc. (IMNM)
Immunome develops antibodies for the treatment of cancer and infectious diseases. This graph reflects the early stages of commercialization of its scientific platform. Any revenue per employee likely comes from grants or strategic partnerships, and its growth signals the interest of major pharmaceutical companies in Immunome's technologies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immunome-Inc.-IMNM&v=1772612429138 "Sales chart per company employee Immunome Inc. (IMNM)")
Sales per employee in the market segment - Pharma immune
Immunome uses a unique antibody discovery platform, which requires elite scientific talent. This chart provides an insight into the team's productivity. It shows how revenue generated (possibly from partnerships or grants) per researcher compares to the average in the highly competitive immunopharmaceutical sector.
Sales per employee for the market as a whole
Immunome (IMNM) is a biotech company whose platform aims to discover new classes of antibodies for cancer treatment. While in clinical trials, the company has not yet generated commercial revenue from its products. This chart illustrates a typical R&D situation: the company invests in its research staff, which generates not current revenue but future patents.
Short shares by company, segment and market as a whole
Shares shorted by company Immunome Inc. (IMNM)
Immunome is a biotech company developing antibodies for the treatment of cancer and infectious diseases. The company is in its early stages, and its platform has no commercial products yet. This chart shows high bearish interest, which is typical for such companies: investors are betting against the success of its lengthy and expensive clinical development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immunome-Inc.-IMNM&v=1772612429174 "Short Shares Chart for the Company Immunome Inc. (IMNM)")
Shares shorted by market segment - Pharma immune
Immunome is a biotech company using a platform to interrogate human memory B cells to discover new cancer antibodies. This metric measures pessimism. "Shorts" here represent a bet that their scientific platform will fail to produce a successful drug candidate or that their trials will fail.
Shares shorted by the overall market
Immunome (IMNM) is a biotech company that uses a unique platform to interrogate human memory B cells to discover powerful antibodies to treat cancer and infections. This is cutting-edge science. This chart shows skepticism about their platform. Bears are betting that their approach is too complex and won't lead to effective drugs, or that the company won't be able to compete with oncology giants.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immunome Inc. (IMNM)
Immunome is a clinical-stage biotech. The stock is extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks, funding concerns, or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immunome-Inc.-IMNM&v=1772612429245 "RSI 14 indicator chart for the company's stock Immunome Inc. (IMNM)")
RSI 14 Market Segment - Pharma immune
Immunome (IMNM) is a biotech company focused on antibody hunting. Their platform sifts through the human immune system's memory to discover cancer drugs. The RSI_14_Seg for "Pharma-immune" shows whether the entire biotech segment is overheated. The chart helps us understand: is IMNM's volatility a reflection of their platform or just general hype?
RSI 14 for the overall market
Immunome (IMNM) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMNM (Immunome Inc.)
Immunome (IMNM) is a biotech company using a platform for "reading" the human immune response to discover new oncology drugs. This chart shows the average target price. It reflects analysts' opinions on the potential of this platform and their expectations based on early clinical data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMNM-Immunome-Inc.&v=1772612429261 "A chart showing analyst consensus forecasts for the expected stock price. IMNM (Immunome Inc.)")
The difference between the consensus estimate and the actual stock price IMNM (Immunome Inc.)
Immunome is a biotech company that uses its platform to detect antibodies from the plasma of cancer survivors to develop new therapies. This chart shows the difference between the market's current valuation of the company and the analyst consensus target. This reflects their confidence in this unique research platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMNM-Immunome-Inc.&v=1772612429263 "A chart showing the difference between the consensus forecast and the actual stock price. IMNM (Immunome Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Immunome is a biotech company that interrogates the human immune system to discover powerful antibodies and cell therapies to fight cancer and infections. This chart shows analysts' overall expectations for the entire immunopharmaceutical sector, reflecting the confidence experts have in this R&D platform.
Analysts' consensus forecast for the overall market share price
Immunome is a biotech company that uses the memory of the human immune system (B cells) to discover and develop new antibodies against cancer and infectious diseases. This chart shows overall market sentiment. For Immunome, a science-based company, how overall risk appetite (sentiment) influences funding for their innovative platform is important. (348)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immunome Inc.
Immunome (IMNM) is a clinical-stage biotech focused on the human immune system. They use their B-cell interrogation platform to discover powerful antibodies to treat cancer and infections. This chart represents pure R&D. Its valuation reflects the market's faith in their unique scientific platform and early clinical trial data.
AKIMA Market Segment Index - Pharma immune
Immunome (IMNM) is a clinical-stage biotech focused on cancer immunotherapy; the company uses its R&D platform to discover new antibodies for cancer treatment. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does IMNM's R&D focus on cancer differentiate it from the average pharma company?
The AKIM Index for the overall market
Immunome is a biotech company using a human B-cell platform to discover new cancer treatments. It recently acquired assets to expand its portfolio. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this transformative R&D story compares to overall economic trends.
